In advanced lung adenocarcinoma, particularly in cases harboring epidermal growth factor receptor (EGFR) gene mutations, EGFR tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line therapy. This evidence concerns the gene EGFR and lung adenocarcinoma.